Skip to main content

Table 3 Unadjusted and Adjusted Associations of sxKOA and Chair Stands with Incident CVD

From: Contributions of symptomatic osteoarthritis and physical function to incident cardiovascular disease

Variable Unadjusted Model 1a Model 2a
OR (95% CI) OR (95% CI) OR (95% CI)
sxKOA vs. no sxKOA at baseline 1.50 (1.08, 2.08) 1.28 (0.90, 1.80) 1.24 (0.86, 1.79)
Baseline 5 chair stand time Q2 vs. Q1** 1.77 (1.14, 2.75) 1.82 (1.17, 2.83) 1.77 (1.13, 2.78)
Baseline 5 chair stand time Q3 vs. Q1** 1.93 (1.25, 2.98) 2.04 (1.31, 3.16) 1.79 (1.14, 2.81)
Baseline 5 chair stand time Q4 vs. Q1** 1.85 (1.21, 2.82) 2.02 (1.30, 3.15) 1.65 (1.02, 2.65)
Baseline 5 chair stand time unable vs. Q1** 2.50 (1.36, 4.58) 2.14 (1.16, 3.98) 1.71 (0.89, 3.27)
Worsened 5 Chair stand time vs. unchanged or improved 1.50 (1.15, 1.94) 1.58 (1.20, 2.08) 1.45 (1.09, 1.93)
Age: 1 year increase    1.01 (1.00, 1.03)
Gender: Female vs. Male    1.46 (1.05, 2.04)
Race: Black vs. White    1.11 (0.82, 1.52)
Education: <HS vs. HS or greater    0.95 (0.68, 1.31)
Cohort: Enrichment vs. Original    1.06 (0.77, 1.47)
BMI: 1 kg/m2 increase    0.98 (0.96, 1.01)
WHR: 0.1 unit increase    1.16 (0.99, 1.36)
Diabetes vs. not    1.91 (1.26, 2.89)
Hypertension vs. not    1.13 (0.84, 1.52)
High cholesterol vs. not    1.03 (0.74, 1.44)
NSAIDs vs. not    1.30 (0.97, 1.74)
  1. CI confidence interval, Q quarter, sxKOA symptomatic knee osteoarthritis, HS high school, BMI body mass index, WHR waist-to-hip ratio, NSAIDs non-steroidal anti-inflammatory drugs
  2. aModels 1 and 2 are adjusted for all variables with data listed in the column